Forum für

Autisten und interessierte Zeitgenossen

Everolimus (RAD-001) ist ein Immunsuppressivum mit Makrolidstruktur (makrocyclisches Lacton) und gehört zur Medikamentenklasse der mTOR-Inhibitoren. Es wird von Novartis in der Transplantationsmedizin unter den Namen Certican® (Europa) und Zortress® (USA) und in der Onkologie unter dem Namen Afinitor® vertrieben.

Derzeit laufen klinische Studien zum Einsatz bei Patienten mit Brustkrebs, Magenkrebs, Leberzellkrebs und Malignen Lymphomen. Daneben wurde über die Verwendung von Everolimus bei einer refraktären chronischen Graft-versus-Host-Reaktion berichtet.

Many prescription drugs are interchangeable to some extent when it comes to treating illnesses and conditions, and now scientists have discovered that certain cancer drugs could be effective in treating those diagnosed with autism.

[...]

Charis Eng is a PTEN expert at the Cleveland Clinic in Ohio and has experience in treating dozens of children with this condition. She first made the connection between cancer and autism in 2005 and teamed up with clinical psychologist Thomas Frazier too. Together they explored how PTEN mutations affect people with autism in hopes to find targeted treatments for their patients. As part of their research, the team compared 17 children who have PTEN-ASD against 16 children with autism and large heads, 38 with just autism, and 14 with no symptoms as a control group. The results showed that compared to the others, those with PTEN-ASD had lower PTEN protein levels and enlarged volumes of white matter. Also, the children themselves had slower processing skills and a poorer memory than the other children. This indicates that low PTEN levels impair cognition by enhancing white matter abnormalities.

Currently, there is no cure for either autism or cancer, but treatment for cancer is much more common. This new link provides us with a hope that there is a clear path forward in treating autism, through the help of cancer treatments. Eng and Frazier are planning to launch their next trial very soon that will involve patients taking the cancer drug everolimus (a safer alternative to rapamycin) for six months in a bid to improve their patient’s brain function.

Brustkrebs

5-Fluoruracil
+ Anthrazyklin
+ Cyclophosphamid
evtl. Capecitabin

Zusätzliche Therapie

Trastuzumab bei HER2-positiven Tumoren
Tamoxifen
Lapatinib
Sunitinib
Eribulin
Everolimus